Theseus Pharmaceuticals, Inc. THRX
We take great care to ensure that the data presented and summarized in this overview for Theseus Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding THRX
View all-
Foresite Capital Opportunity Management V, LLC Larkspur, CA959KShares$016.71% of portfolio
-
Tekla Capital Management LLC75KShares$00.03% of portfolio
-
Goldman Sachs Group Inc New York, NY30.4KShares$00.0% of portfolio
-
Ever Source Wealth Advisors, LLC267Shares$00.0% of portfolio
Latest Institutional Activity in THRX
Top Purchases
Top Sells
About THRX
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Transactions at THRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2024
|
Bradford D. Dahms President and CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,150
-100.0%
|
-
|
|
Feb 14
2024
|
Iain D. Dukes Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
388,324
-100.0%
|
-
|
|
Feb 14
2024
|
Carl L Gordon Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
17,713,600
-100.0%
|
-
|
|
Feb 14
2024
|
Donald J Hayden Jr Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Feb 14
2024
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
17,713,600
-100.0%
|
-
|
|
Nov 06
2023
|
William Shakespeare Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
251,084
+28.2%
|
$0
$0.32 P/Share
|
|
Jul 17
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
479,932
+10.39%
|
$1,439,796
$3.05 P/Share
|
|
Jul 17
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
479,932
+10.39%
|
$1,439,796
$3.05 P/Share
|
|
Jul 17
2023
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
700,000
+11.3%
|
$1,400,000
$2.97 P/Share
|
|
Dec 30
2022
|
Donald J Hayden Jr Director |
BUY
Open market or private purchase
|
Direct |
9,900
+49.75%
|
$49,500
$5.0 P/Share
|
|
Dec 29
2022
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+11.83%
|
$2,500,000
$5.0 P/Share
|
|
Dec 29
2022
|
Donald J Hayden Jr Director |
BUY
Open market or private purchase
|
Direct |
100
+50.0%
|
$500
$5.0 P/Share
|
|
Nov 30
2022
|
Bradford D. Dahms President and CFO |
BUY
Open market or private purchase
|
Direct |
1,502
+19.65%
|
$9,012
$6.66 P/Share
|
|
Nov 11
2022
|
Timothy P Clackson President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.71%
|
$15,000
$6.8 P/Share
|
|
Nov 07
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
192,000
+1.13%
|
$960,000
$5.21 P/Share
|
|
Nov 07
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
192,000
+1.13%
|
$960,000
$5.21 P/Share
|
|
Jan 21
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
111,896
+0.67%
|
$1,007,064
$9.97 P/Share
|
|
Jan 21
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
111,896
+0.67%
|
$1,007,064
$9.97 P/Share
|
|
Jan 20
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.21%
|
$315,000
$9.95 P/Share
|
|
Jan 20
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.21%
|
$315,000
$9.95 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.66M shares |
|---|---|
| Exercise of conversion of derivative security | 251K shares |
| Disposition due to a tender of shares in a change of control transaction | 35.8M shares |
|---|